Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
November 01 2023 - 4:00PM
Gracell Biotechnologies Inc. ("Gracell" or the "Company",
NASDAQ: GRCL), a global clinical-stage biopharmaceutical company
dedicated to developing innovative and highly efficacious cell
therapies for the treatment of cancer and autoimmune disease, today
announced that the management team will participate in four
upcoming investor conferences in November.
Stifel 2023 Healthcare ConferenceFireside Chat:
Tuesday, November 14th at 1:15 pm ETOne-on-one meetings: November
14th, 2023Presenter: Dr. Kevin Xie, Chief Financial
OfficerLocation: New York
Jefferies London Healthcare Conference Fireside
Chat: Wednesday, November 15th at 11:30 am GMT / 6:30 am
ETOne-on-one meetings: November 15th and 16th, 2023Presenter: Dr.
Kevin Xie, Chief Financial OfficerLocation: London
Piper Sandler 35th
Annual Healthcare ConferencePresentation: Tuesday,
November 28th at 12:00 pmOne-on-one meetings: November 28th,
2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New
York
6th Annual Evercore ISI HealthCONx
ConferencePresentation: Wednesday, November 29th at 9:35
am ETOne-on-one meetings: November 29th and 30th, 2023Presenter:
Dr. Kevin Xie, Chief Financial OfficerLocation: Miami
Available webcasts of the presentations will be posted on the
News and Events section of the Company's website. A replay of
the webcast will be available for 90 days following the event. For
more information, please visit ir.gracellbio.com.
About GracellGracell Biotechnologies Inc.
(“Gracell”) is a global clinical-stage biopharmaceutical company
dedicated to discovering and developing breakthrough cell therapies
for the treatment of cancers and autoimmune diseases. Leveraging
its innovative FasTCAR and TruUCAR technology platforms and SMART
CART™ technology module, Gracell is developing a rich
clinical-stage pipeline of multiple autologous and allogeneic
product candidates with the potential to overcome major industry
challenges that persist with conventional CAR-T therapies,
including lengthy manufacturing time, suboptimal cell quality, high
therapy cost, and lack of effective CAR-T therapies for solid
tumors and autoimmune diseases. The lead candidate BCMA/CD19
dual-targeting FasTCAR-T GC012F is currently being evaluated in
clinical studies for the treatment of multiple myeloma, B-NHL and
systemic lupus erythematosus (SLE). For more information on
Gracell, please visit www.gracellbio.com. Follow @GracellBio
on LinkedIn.
Media contact
Marvin Tang
marvin.tang@gracellbio.com
Investor contact
Gracie Tong
gracie.tong@gracellbio.com
Gracell Biotechnologies (NASDAQ:GRCL)
Historical Stock Chart
From Apr 2024 to May 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Historical Stock Chart
From May 2023 to May 2024